| Study characteristics |
| Methods |
C: sequentially numbered identical syringes
Double‐blinded
Ex during trial: none
Losses to FU: none |
| Participants |
The Netherlands
60 participants
78% > 70 years
52% male
100% CT before entry
Ischaemic stroke less than 72 hours since stroke onset |
| Interventions |
Rx: dalteparin (LMWH, Kabi 2165) 2500 anti‐Xa units subcutaneous 12‐ hourly
Control: placebo
Duration: 14 days |
| Outcomes |
Death plus cause of death
DVT (systematic I‐125 scan with venography)
PE
ICH (symptomatic plus systematic CT)
Major extracranial haemorrhage |
| Notes |
Ex: coma
FU: 14 days |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
No report on method used for randomisation generation |
| Allocation concealment (selection bias) |
Unclear risk |
No report on method used for allocation concealment |
| Blinding (performance bias and detection bias)
All outcomes |
Low risk |
Tested using a double‐blind, placebo‐controlled, randomised trial design. with 30 patients allocated to each group |
| Blinding of participants and personnel (performance bias)
All outcomes |
Low risk |
Mentioned double‐blinded |
| Blinding of outcome assessment (detection bias)
All outcomes |
Low risk |
Mentioned double‐blinded |
| Incomplete outcome data (attrition bias)
All outcomes |
Low risk |
No report of loss to follow‐up during 14 days |
| Selective reporting (reporting bias) |
Unclear risk |
Abstract with no detailed information |
